Apexigen Receives $20M Series A1 Financing
By Catherine Shaffer
Tuesday, August 6, 2013
Apexigen Inc., of Burlingame, Calif., reeled in a $20 million Series A1 financing to advance its cancer therapy, APX005. Ankey Ventures LLC led the financing, with participation from WSR Capital, China Development Industrial Bank, Themes Investment Partners and Sycamore Ventures.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.